Singapore markets open in 1 hour 17 minutes

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
32.90-2.30 (-6.53%)
At close: 04:00PM EST
32.86 -0.04 (-0.12%)
After hours: 04:56PM EST
Full screen
Loading interactive chart…
  • Business Wire

    Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

    MONROVIA, Calif., January 11, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones.

  • Business Wire

    Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

    MONROVIA, Calif., January 06, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.

  • Business Wire

    Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

    MONROVIA, Calif., December 12, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poste